On Wednesday, Medicare began a temporary program that allows qualifying adults to access popular weight loss medications at reduced prices. Under the Medicare GLP-1 Bridge program, eligible participants can obtain medications like semaglutide (Wegovy) and tirzepatide (Zepbound) for $50 per month. To qualify, individuals must be 18 or older, enrolled in Medicare Part D, and have a body mass index (BMI) of 35 or higher, among other health criteria, according to the Centers for Medicare & Medicaid Services.
Key Details
This initiative aims to alleviate the financial burden of weight loss medications, which many users find costly. Barbara Senich, a 69-year-old participant, shared her experience of losing weight with GLP-1 medications, stating,
This is the thing that’s been the miracle for me, is the maintenance.
However, she noted that her Medicare plan does not currently cover these medications, making the new program significant for many like her.
The introduction of the program comes amid rising obesity rates in the U.S. and a growing demand for effective weight management solutions. According to the CDC, approximately 42% of American adults are classified as obese, highlighting the need for accessible treatment options.
Background
The program is expected to run temporarily, and its future will depend on evaluations of its effectiveness and cost implications for the Medicare program. The Centers for Medicare & Medicaid Services has not yet disclosed how long the program will last.
Related coverage: Record Heat Waves Hit Europe and US Amid Climate Concerns.
This initiative could influence the pharmaceutical sector, particularly companies producing GLP-1 medications, as increased access may lead to higher sales volumes. Investors will watch for updates on the program's duration and potential expansions in coverage for weight loss drugs under Medicare.